InsiderTrades

Form 4 for ZVRA ZEVRA THERAPEUTICS, INC.

Accepted 2021-08-24 00:00:00 ET · period of report 2021-08-20 · accession 0001437749-21-020865 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2021-08-24 2021-08-24 ZVRA Mickle Travis C Pres, CEO, Dir J - Other $0.00 -96.5K 0 -100% $0
DMI 2021-08-24 2021-08-24 ZVRA Mickle Travis C Pres, CEO, Dir J - Other $0.00 +87.1K 0 New $0
D 2021-08-24 2021-08-20 ZVRA Mickle Travis C Pres, CEO, Dir A - Grant $0.00 +263.7K 263.7K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-08-24 J A 1,341 $0.00 32,396 D — —
2 Common Common Stock 2021-08-24 J D 3,125 $0.00 29,271 D — —
3 Common Common Stock 2021-08-24 J A 7,701 $0.00 31,055 D — —
4 Common Common Stock 2021-08-24 J D 96,153 $0.00 23,354 D By Mickle Holdings LLC — — (F1) The Reporting Person is the sole manager member of Mickle Holdings, LLC.
5 Common Common Stock 2021-08-24 J A 96,153 $0.00 96,153 I By Travis C. Mickle & Christal M.M. Mickle TRS UA 4-30-09 Mickle Family Trust, co-trustee — —
6 Common Common Stock 2021-08-24 J D 7,701 $0.00 0 I By Travis C. Mickle & Christal M.M. Mickle TRS UA 4-30-09 TCM Family Trust, co-trustee — —
7 Common Common Stock 2021-08-24 J D 1,341 $0.00 0 I — —
8 Common Common Stock 2021-08-24 J D 6,287 $0.00 0 D — — (F4) Common stock that was previously held jointly by the Reporting Person and Christal M.M. Mickle, and is now held solely by Ms. Mickle.
9 Derivative Stock Option (right to buy) 2021-08-20 A A 263,743 $0.00 263,743 D $9.06 · — to 2031-08-19 263,743 Common Stock (F6) Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on August 20, 2022 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.